HIF1A and urogenital neoplasm: To verify whether the constructed biosensor can simultaneously determine HIF-1α, ANG-2, and IL-1β in natural samples, testing was performed on plasma from patients with inflammation of the prostate (as a control group) and a study group of patients with diagnosed bladder cancer.